Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aligos Therapeutics

< Previous 1 2 Next >
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule,
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics To Present Late Breaking Poster on ALG-000184, its CAM-E Drug Candidate, at The Liver Meeting® 2023
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces $92 Million Private Placement Financing
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
From Aligos Therapeutics
Via GlobeNewswire
Tickers ALGS
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.